Iasis Molecular

company

About

Iasis Molecular is an antimicrobial solutions company developing technologies to fight the threat of antibiotic resistant bacteria.

  • 1 - 10

Details

Last Funding Type
Grant
Last Funding Money Raised
$1.25M
Industries
Biotechnology
Founded date
Jan 1, 2008
Number Of Employee
1 - 10
Operating Status
Active

Iasis Molecular Sciences & Novion Technologies have pioneered and patented a family of technologies aimed at minimizing health care-acquired implantable medical device-related infection, wound infections associated with surgical procedures, and for the treatment of infection(s) and tissue loss associated with chronic wounds and burn trauma. The proprietary antimicrobial agent technologies are of rational design, elegantly simple, and cost effective thus allowing patients of all ages and walks of life to benefit.

Encouraging preclinical testing results have generated enthusiasm that they are on a path to providing value added, life-quality improving solutions for patients requiring implantable medical device therapies, those afflicted by topical infection, inflammation, and secondary tissue loss associated with burn trauma, periodontal disease, and abnormal healing such as with chronic wounds.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$1.25M
Iasis Molecular has raised a total of $1.25M in funding over 2 rounds. Their latest funding was raised on Jan 25, 2022 from a Grant round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jan 25, 2022 Grant $1.25M 1 Congressionally Directed Medical Research Programs Detail
Aug 1, 2016 Seed 1 Detail

Investors

Number of Lead Investors
Number of Investors
1
2
Iasis Molecular is funded by 2 investors. Congressionally Directed Medical Research Programs and Mountain Man Ventures are the most recent investors.
Investor Name Lead Investor Funding Round
Congressionally Directed Medical Research Programs Yes Grant
Mountain Man Ventures Seed